1
|
Dong J, Cross RW, Doyle MP, Kose N, Mousa JJ, Annand EJ, Borisevich V, Agans KN, Sutton R, Nargi R, Majedi M, Fenton KA, Reichard W, Bombardi RG, Geisbert TW, Crowe JE. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein. Cell 2021; 183:1536-1550.e17. [PMID: 33306954 DOI: 10.1016/j.cell.2020.11.023] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 10/04/2020] [Accepted: 11/12/2020] [Indexed: 01/01/2023]
Abstract
Hendra (HeV) and Nipah (NiV) viruses are emerging zoonotic pathogens in the Henipavirus genus causing outbreaks of disease with very high case fatality rates. Here, we report the first naturally occurring human monoclonal antibodies (mAbs) against HeV receptor binding protein (RBP). All isolated mAbs neutralized HeV, and some also neutralized NiV. Epitope binning experiments identified five major antigenic sites on HeV-RBP. Animal studies demonstrated that the most potent cross-reactive neutralizing mAbs, HENV-26 and HENV-32, protected ferrets in lethal models of infection with NiV Bangladesh 3 days after exposure. We solved the crystal structures of mAb HENV-26 in complex with both HeV-RBP and NiV-RBP and of mAb HENV-32 in complex with HeV-RBP. The studies reveal diverse sites of vulnerability on RBP recognized by potent human mAbs that inhibit virus by multiple mechanisms. These studies identify promising prophylactic antibodies and define protective epitopes that can be used in rational vaccine design.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/isolation & purification
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/immunology
- Antigens, Viral/immunology
- Binding Sites
- Binding, Competitive
- Brain/pathology
- Chiroptera/virology
- Cross Reactions/immunology
- Crystallography, X-Ray
- Ephrin-B2/metabolism
- Female
- Ferrets/virology
- Hendra Virus/immunology
- Henipavirus/immunology
- Humans
- Interferometry
- Liver/pathology
- Models, Molecular
- Neutralization Tests
- Nipah Virus/immunology
- Protein Binding
- Protein Conformation
- Protein Domains
- Receptors, Virus/chemistry
- Receptors, Virus/immunology
- Receptors, Virus/metabolism
Collapse
Affiliation(s)
- Jinhui Dong
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Robert W Cross
- Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA
| | - Michael P Doyle
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Nurgun Kose
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Jarrod J Mousa
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Edward J Annand
- Sydney School of Veterinary Science and Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia; Black Mountain Laboratories & Australian Centre for Disease Preparedness, Health and Biosecurity, CSIRO, Canberra, ACT, Australia
| | - Viktoriya Borisevich
- Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA
| | - Krystle N Agans
- Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA
| | - Rachel Sutton
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Rachel Nargi
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Mahsa Majedi
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Karla A Fenton
- Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA
| | - Walter Reichard
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Robin G Bombardi
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Thomas W Geisbert
- Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA
| | - James E Crowe
- The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
| |
Collapse
|
2
|
Abstract
Nipah instead was one of the most fatal outbreaks of diseases in the mankind which was initially assumed as Japanese encephalitis. A multidisciplinary exploration was done at several levels of microbiology, histopathology and genetics which led to the discovery of a new paramyxovirus named Nipah virus (NiV). The disease was primarily identified in Malaysia in 1998 and named after a village, Sungai Nipah. The main mode of transmission in the Malaysian outbreaks was thought to be the consumption of bat’s dropping, urine and fruit partially eaten by pigs. In Bangladesh and northeast India, the virus was directly transmitted from bats to human through consumption of raw date palm juice. To limit the epidemic, coordinated efforts by health care providers have become mandatory. This article gives a note about the NiV, its infection and on-going researches on its management strategies. Data were collected using electronic media consisting of articles, books and websites.
Collapse
Affiliation(s)
- Ruchi D Raval
- Department of Periodontics & Implantology, Manubhai Patel Dental College, Munjmahuda, Vadodara 390011, India
| | - Mansi Mehta
- Dr. Bristol Dental, Bristol, Connecticut, USA
| |
Collapse
|